Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ephedrine Sulfate injection USP, 50 mg/mL Single Dose vial, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) AKOVAZ, from Exela Pharma Sciences LLC.
Ephedrine Sulfate injection USP, 50 mg/mL is indicated for the treatment of clinically important hypotension occurring in the setting of anaesthesia. According to IQVIATM (IMS Health), Ephedrine Sulfate injection USP 50 mg/mL had US sales of approximately $36 million for the 12-month period ending May 2024.
Shares of Caplin Point Laboratories Limited was last trading in BSE at Rs. 1500.30 as compared to the previous close of Rs. 1527.50. The total number of shares traded during the day was 10708 in over 1405 trades.
The stock hit an intraday high of Rs. 1527.50 and intraday low of 1460.25. The net turnover during the day was Rs. 15980177.00. |
